Small molecules from natural sources, targeting signaling pathways in diabetes

Biochimica et Biophysica Acta - Gene Regulatory Mechanisms

Volumn 1799, Issue 10-12, 2010, Pages 854-865

  Liu, Qiong ^a   Chen, Lili ^a   Hu, Lihong ^a   Guo, Yuewei ^a   Shen, Xu ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

AMP activated protein kinase; Diabetes; Endoplasmic reticulum stress; Insulin; Natural product

Indexed keywords

FATTY ACID; INSULIN; INSULIN RECEPTOR; MASLINIC ACID; NAUCLEA LATIFOLIA EXTRACT; OLEANOLIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN TYROSINE KINASE; RESVERATROL; TRICHOSTATIN A; URSOLIC ACID;

CARBOHYDRATE METABOLISM; CHROMATIN STRUCTURE; CONFORMATIONAL TRANSITION; DIABETES MELLITUS; ENDOPLASMIC RETICULUM STRESS; EPIGENETICS; GENE FUNCTION; GLUCONEOGENESIS; GLYCOGENOLYSIS; INSULIN METABOLISM; INSULIN RELEASE; INSULIN RESISTANCE; PRIORITY JOURNAL; REVIEW; SECRETORY PATHWAY; SIGNAL TRANSDUCTION;

AGED; ANIMALS; CARBOHYDRATE METABOLISM; CHROMATIN; DIABETES MELLITUS; HUMANS; HYPOGLYCEMIC AGENTS; INFLAMMATION; INSULIN; MIDDLE AGED; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; PLANTS; SIGNAL TRANSDUCTION; UNFOLDED PROTEIN RESPONSE;

EID: 78649835553     PISSN: 18749399     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbagrm.2010.06.004     Document Type: Review

References (84)

1. Prabhakar P.K., Doble M. A target based therapeutic approach towards diabetes mellitus using medicinal plants. Curr. Diab. Rev. 2008, 4:291-308.
2. Mohler M.L., He Y., Wu Z., Hwang D.J., Miller D.D. Recent and emerging anti-diabetes targets. Med. Res. Rev. 2009, 29:125-195.
3. Diagnosis and classification of diabetes mellitus. Diab. Care 2004, 27(Suppl 1):S5-S10.
4. Ashok J.M.R., Tiwari K. Diabetes mellitus and multiple therapeutic approaches of phytochemicals: present status and future prospects. Curr. Sci. 2002, 83:30-38.
5. Marx J. Unraveling the causes of diabetes. Science 2002, 296:686-689.
6. Rother K.I. Diabetes treatment-bridging the divide. N Engl J. Med. 2007, 356:1499-1501.
7. Huang X.F., Chen J.Z. Obesity, the PI3K/Akt signal pathway and colon cancer. Obes. Rev. 2009, 10:610-616.
8. Henke B.R., Sparks S.M. Glycogen phosphorylase inhibitors. Mini Rev. Med. Chem. 2006, 6:845-857.
9. Hardie D.G. AMP-activated protein kinase as a drug target. Annu. Rev. Pharmacol. Toxicol. 2007, 47:185-210.
10. Ozcan U., Cao Q., Yilmaz E., Lee A.H., Iwakoshi N.N., Ozdelen E., Tuncman G., Gorgun C., Glimcher L.H., Hotamisligil G.S. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 2004, 306:457-461.
11. Frayn K.N., Fielding B.A., Karpe F. Adipose tissue fatty acid metabolism and cardiovascular disease. Curr. Opin. Lipidol. 2005, 16:409-415.
12. Balint B.L., Nagy L. Selective modulators of PPAR activity as new therapeutic tools in metabolic diseases. Endocr. Metab. Immune Disord. Drug Targets 2006, 6:33-43.
13. Gray S.G., De Meyts P. Role of histone and transcription factor acetylation in diabetes pathogenesis. Diab. Metab. Res. Rev. 2005, 21:416-433.
14. Hales C.N., Barker D.J. Type 2 (non-insulin-dependent) diabetes mellitus: the thrifty phenotype hypothesis. Diabetologia 1992, 35:595-601.
15. Moller D.E. New drug targets for type 2 diabetes and the metabolic syndrome. Nature 2001, 414:821-827.
16. Ivorra M.D., Paya M., Villar A. A review of natural products and plants as potential antidiabetic drugs. J. Ethnopharmacol. 1989, 27:243-275.
17. Vuksan V., Sievenpiper J.L. Herbal remedies in the management of diabetes: lessons learned from the study of ginseng. Nutr. Metab. Cardiovasc. Dis. 2005, 15:149-160.
18. Saltiel A.R., Kahn C.R. Insulin signalling and the regulation of glucose and lipid metabolism. Nature 2001, 414:799-806.
19. Kim H., Deng L., Xiong X., Hunter W.D., Long M.C., Pirrung M.C. Glyceraldehyde 3-phosphate dehydrogenase is a cellular target of the insulin mimic demethylasterriquinone B1. J. Med. Chem. 2007, 50:3423-3426.
20. Zhang B., Salituro G., Szalkowski D., Li Z., Zhang Y., Royo I., Vilella D., Diez M.T., Pelaez F., Ruby C., Kendall R.L., Mao X., Griffin P., Calaycay J., Zierath J.R., Heck J.V., Smith R.G., Moller D.E. Discovery of a small molecule insulin mimetic with antidiabetic activity in mice. Science 1999, 284:974-977.
21. Liu K., Xu L., Szalkowski D., Li Z., Ding V., Kwei G., Huskey S., Moller D.E., Heck J.V., Zhang B.B., Jones A.B. Discovery of a potent, highly selective, and orally efficacious small-molecule activator of the insulin receptor. J. Med. Chem. 2000, 43:3487-3494.
22. Weber M.A., Lidor A., Arora S., Salituro G.M., Zhang B.B., Sidawy A.N. A novel insulin mimetic without a proliferative effect on vascular smooth muscle cells. J. Vasc. Surg. 2000, 32:1118-1126.
23. Qureshi S.A., Ding V., Li Z., Szalkowski D., Biazzo-Ashnault D.E., Xie D., Saperstein R., Brady E., Huskey S., Shen X., Liu K., Xu L., Salituro G.M., Heck J.V., Moller D.E., Jones A.B., Zhang B.B. Activation of insulin signal transduction pathway and anti-diabetic activity of small molecule insulin receptor activators. J. Biol. Chem. 2000, 275:36590-36595.
24. Lin B., Li Z.T., Park K., Deng L., Pai A., Zhong L., Pirrung M.C., Webster N.J.G. Identification of novel orally available small molecule insulin mimetics. J. Pharmacol. Exp. Ther. 2007, 323:579-585.
25. Elchebly M., Payette P., Michaliszyn E., Cromlish W., Collins S., Loy A.L., Normandin D., Cheng A., Himms-Hagen J., Chan C.C., Ramachandran C., Gresser M.J., Tremblay M.L., Kennedy B.P. Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene. Science 1999, 283:1544-1548.
26. Nishino H., Nishino A., Takayasu J., Hasegawa T., Iwashima A., Hirabayashi K., Iwata S., Shibata S. Inhibition of the tumor-promoting action of 12-O-tetradecanoylphorbol-13-acetate by some oleanane-type triterpenoid compounds. Cancer Res. 1988, 48:5210-5215.
27. Liu J. Pharmacology of oleanolic acid and ursolic acid. J. Ethnopharmacol. 1995, 49:57-68.
28. Sato H., Genet C., Strehle A., Thomas C., Lobstein A., Wagner A., Mioskowski C., Auwerx J., Saladin R. Anti-hyperglycemic activity of a TGR5 agonist isolated from Olea europaea. Biochem. Biophys. Res. Commun. 2007, 362:793-798.
29. Zhang W., Hong D., Zhou Y., Zhang Y., Shen Q., Li J.Y., Hu L.H., Li J. Ursolic acid and its derivative inhibit protein tyrosine phosphatase 1B, enhancing insulin receptor phosphorylation and stimulating glucose uptake. Biochim. Biophys. Acta 2006, 1760:1505-1512.
30. Zhang Y.N., Zhang W., Hong D., Shi L., Shen Q., Li J.Y., Li J., Hu L.H. Oleanolic acid and its derivatives: new inhibitor of protein tyrosine phosphatase 1B with cellular activities. Bioorg. Med. Chem. 2008, 16:8697-8705.
31. Lin Z., Zhang Y., Zhang Y., Shen H., Hu L., Jiang H., Shen X. Oleanolic acid derivative NPLC441 potently stimulates glucose transport in 3T3-L1 adipocytes via a multi-target mechanism. Biochem. Pharmacol. 2008, 76:1251-1262.
32. Sun T., Wang Q., Yu Z., Zhang Y., Guo Y., Chen K., Shen X., Jiang H. Hyrtiosal, a PTP1B inhibitor from the marine sponge Hyrtios erectus, shows extensive cellular effects on PI3K/AKT activation, glucose transport, and TGFbeta/Smad2 signaling. Chembiochem 2007, 8:187-193.
33. Hara T., Hirasawa A., Sun Q., Sadakane K., Itsubo C., Iga T., Adachi T., Koshimizu T.A., Hashimoto T., Asakawa Y., Tsujimoto G. Novel selective ligands for free fatty acid receptors GPR120 and GPR40. Naunyn-Schmiedebergs Arch. Pharmacol. 2009, 380:247-255.
34. Schnell S., Schaefer M., Schofl C. Free fatty acids increase cytosolic free calcium and stimulate insulin secretion from beta-cells through activation of GPR40. Mol. Cell. Endocrinol. 2007, 263:173-180.
35. Latour M.G., Alquier T., Oseid E., Tremblay C., Jetton T.L., Luo J., Lin D.C., Poitout V. GPR40 is necessary but not sufficient for fatty acid stimulation of insulin secretion in vivo. Diabetes 2007, 56:1087-1094.
36. Christiansen E., Urban C., Merten N., Liebscher K., Karlsen K.K., Hamacher A., Spinrath A., Bond A.D., Drewke C., Ullrich S., Kassack M.U., Kostenis E., Ulven T. Discovery of potent and selective agonists for the free fatty acid receptor 1 (FFA(1)/GPR40), a potential target for the treatment of type II diabetes. J. Med. Chem. 2008, 51:7061-7064.
37. Hirasawa A., Tsumaya K., Awaji T., Katsuma S., Adachi T., Yamada M., Sugimoto Y., Miyazaki S., Tsujimoto G. Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120. Nat. Med. 2005, 11:90-94.
38. Aiston S., Coghlan M.P., Agius L. Inactivation of phosphorylase is a major component of the mechanism by which insulin stimulates hepatic glycogen synthesis. Eur. J. Biochem. 2003, 270:2773-2781.
39. Fukushima M., Matsuyama F., Ueda N., Egawa K., Takemoto J., Kajimoto Y., Yonaha N., Miura T., Kaneko T., Nishi Y., Mitsui R., Fujita Y., Yamada Y., Seino Y. Effect of corosolic acid on postchallenge plasma glucose levels. Diab. Res. Clin. Pract. 2006, 73:174-177.
40. Wen X., Sun H., Liu J., Wu G., Zhang L., Wu X., Ni P. Pentacyclic triterpenes. Part 1: the first examples of naturally occurring pentacyclic triterpenes as a new class of inhibitors of glycogen phosphorylases. Bioorg. Med. Chem. Lett. 2005, 15:4944-4948.
41. Wen X., Sun H., Liu J., Cheng K., Zhang P., Zhang L., Hao J., Zhang L., Ni P., Zographos S.E., Leonidas D.D., Alexacou K.M., Gimisis T., Hayes J.M., Oikonomakos N.G. Naturally occurring pentacyclic triterpenes as inhibitors of glycogen phosphorylase: synthesis, structure-activity relationships, and X-ray crystallographic studies. J. Med. Chem. 2008, 51:3540-3554.
42. Cheng K., Zhang P., Liu J., Xie J., Sun H. Practical synthesis of bredemolic acid, a natural inhibitor of glycogen phosphorylase. J. Nat. Prod. 2008, 71:1877-1880.
43. Zhu P., Bi Y., Xu J., Li Z., Liu J., Zhang L., Ye W., Wu X. Terpenoids. III: synthesis and biological evaluation of 23-hydroxybetulinic acid derivatives as novel inhibitors of glycogen phosphorylase. Bioorg. Med. Chem. Lett. 2009, 19:6966-6969.
44. Mcgarry J.D. What if Minkowski had been ageusic-an alternative angle on diabetes. Science 1992, 258:766-770.
45. Ruderman N.B., Saha A.K., Vavvas D., Witters L.A. Malonyl-CoA, fuel sensing, and insulin resistance. Am. J. Physiol. Endocrinol. Metab. 1999, 276:E1-E18.
46. Janovska A., Hatzinikolas G., Staikopoulos V., McInerney J., Mano M., Wittert G.A. AMPK and ACC phosphorylation: effect of leptin, muscle fibre type and obesity. Mol. Cell. Endocrinol. 2008, 284:1-10.
47. Saha A.K., Ruderman N.B. Malonyl-CoA and AMP-activated protein kinase: an expanding partnership. Mol. Cell. Biochem. 2003, 253:65-70.
48. Cheng Z., Pang T., Gu M., Gao A.H., Xie C.M., Li J.Y., Nan F.J., Li J. Berberine-stimulated glucose uptake in L6 myotubes involves both AMPK and p38 MAPK. Biochim. Biophys. Acta 2006, 1760:1682-1689.
49. Lee Y.S., Kim W.S., Kim K.H., Yoon M.J., Cho H.J., Shen Y., Ye J.M., Lee C.H., Oh W.K., Kim C.T., Hohnen-Behrens C., Gosby A., Kraegen E.W., James D.E., Kim J.B. Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes 2006, 55:2256-2264.
50. Yin J., Gao Z., Liu D., Liu Z., Ye J. Berberine improves glucose metabolism through induction of glycolysis. Am. J. Physiol. Endocrinol. Metab. 2008, 294:E148-E156.
51. Kim W.S., Lee Y.S., Cha S.H., Jeong H.W., Choe S.S., Lee M.R., Oh G.T., Park H.S., Lee K.U., Lane M.D., Kim J.B. Berberine improves lipid dysregulation in obesity by controlling central and peripheral AMPK activity. Am. J. Physiol. Endocrinol. Metab. 2009, 296:E812-E819.
52. Turner N., Li J.Y., Gosby A., To S.W., Cheng Z., Miyoshi H., Taketo M.M., Cooney G.J., Kraegen E.W., James D.E., Hu L.H., Li J., Ye J.M. Berberine and its more biologically available derivative, dihydroberberine, inhibit mitochondrial respiratory complex I: a mechanism for the action of berberine to activate AMP-activated protein kinase and improve insulin action. Diabetes 2008, 57:1414-1418.
53. Willson T.M., Brown P.J., Sternbach D.D., Henke B.R. The PPARs: from orphan receptors to drug discovery. J. Med. Chem. 2000, 43:527-550.
54. Kim S.N., Choi H.Y., Lee W., Park G.M., Shin W.S., Kim Y.K. Sargaquinoic acid and sargahydroquinoic acid from Sargassum yezoense stimulate adipocyte differentiation through PPARalpha/gamma activation in 3T3-L1 cells. FEBS Lett. 2008, 582:3465-3472.
55. Zou G., Gao Z., Wang J., Zhang Y., Ding H., Huang J., Chen L., Guo Y., Jiang H., Shen X. Deoxyelephantopin inhibits cancer cell proliferation and functions as a selective partial agonist against PPARgamma. Biochem. Pharmacol. 2008, 75:1381-1392.
56. Li Y.T., Li L., Chen J., Hu T.C., Huang J., Guo Y.W., Jiang H.L., Shen X. 7-Chloroarctinone-b as a new selective PPARgamma antagonist potently blocks adipocyte differentiation. Acta Pharmacol. Sin. 2009, 30:1351-1358.
57. Kim I., Xu W., Reed J.C. Cell death and endoplasmic reticulum stress: disease relevance and therapeutic opportunities. Nat. Rev. Drug Discov. 2008, 7:1013-1030.
58. Ron D., Walter P. Signal integration in the endoplasmic reticulum unfolded protein response. Nat. Rev. Mol. Cell Biol. 2007, 8:519-529.
59. Tsiotra P.C., Tsigos C. Stress, the endoplasmic reticulum, and insulin resistance. Ann. NY Acad. Sci. 2006, 1083:63-76.
60. Schroder M., Kaufman R.J. ER stress and the unfolded protein response. Mutat. Res. 2005, 569:29-63.
61. Jeffrey K.D., Alejandro E.U., Luciani D.S., Kalynyak T.B., Hu X., Li H., Lin Y., Townsend R.R., Polonsky K.S., Johnson J.D. Carboxypeptidase E mediates palmitate-induced beta-cell ER stress and apoptosis. Proc. Natl Acad. Sci. USA 2008, 105:8452-8457.
62. Tashiro E., Hironiwa N., Kitagawa M., Futamura Y., Suzuki S., Nishio M., Imoto M. Trierixin, a novel Inhibitor of ER stress-induced XBP1 activation from Streptomyces sp. 1. Taxonomy, fermentation, isolation and biological activities. J. Antibiot. (Tokyo) 2007, 60:547-553.
63. Futamura Y., Tashiro E., Hironiwa N., Kohno J., Nishio M., Shindo K., Imoto M. Trierixin, a novel inhibitor of ER stress-induced XBP1 activation from Streptomyces sp. II. Structure elucidation. J. Antibiot. (Tokyo) 2007, 60:582-585.
64. Wellen K.E., Hotamisligil G.S. Inflammation, stress, and diabetes. J. Clin. Invest. 2005, 115:1111-1119.
65. Hotamisligil G.S. Role of endoplasmic reticulum stress and c-Jun NH2-terminal kinase pathways in inflammation and origin of obesity and diabetes. Diabetes 2005, 54(Suppl 2):S73-S78.
66. Hotamisligil G.S. Inflammation and metabolic disorders. Nature 2006, 444:860-867.
67. Barr R.K., Kendrick T.S., Bogoyevitch M.A. Identification of the critical features of a small peptide inhibitor of JNK activity. J. Biol. Chem. 2002, 277:10987-10997.
68. Scapin G., Patel S.B., Lisnock J., Becker J.W., LoGrasso P.V. The structure of JNK3 in complex with small molecule inhibitors: structural basis for potency and selectivity. Chem. Biol. 2003, 10:705-712.
69. Rochfort S.J., Towerzey L., Carroll A., King G., Michael A., Pierens G., Rali T., Redburn J., Whitmore J., Quinn R.J. Latifolians A and B, novel JNK3 kinase inhibitors from the Papua New Guinean plant Gnetum latifolium. J. Nat. Prod. 2005, 68:1080-1082.
70. Yanti, Lee M., Kim D., Hwang J.K. Inhibitory effect of panduratin A on c-Jun N-terminal kinase and activator protein-1 signaling involved in Porphyromonas gingivalis supernatant-stimulated matrix metalloproteinase-9 expression in human oral epidermoid cells. Biol. Pharm. Bull. 2009, 32:1770-1775.
71. Shoelson S.E., Lee J., Yuan M. Inflammation and the IKK beta/I kappa B/NF-kappa B axis in obesity- and diet-induced insulin resistance. Int. J. Obes. Relat. Metab. Disord. 2003, 27(Suppl 3):S49-S52.
72. Shishodia S., Aggarwal B.B. Guggulsterone inhibits NF-kappaB and IkappaBalpha kinase activation, suppresses expression of anti-apoptotic gene products, and enhances apoptosis. J. Biol. Chem. 2004, 279:47148-47158.
73. Pandey M.K., Sung B., Ahn K.S., Kunnumakkara A.B., Chaturvedi M.M., Aggarwal B.B. Gambogic acid, a novel ligand for transferrin receptor, potentiates TNF-induced apoptosis through modulation of the nuclear factor-kappaB signaling pathway. Blood 2007, 110:3517-3525.
74. Cuaz-Perolin C., Billiet L., Bauge E., Copin C., Scott-Algara D., Genze F., Buchele B., Syrovets T., Simmet T., Rouis M. Antiinflammatory and antiatherogenic effects of the NF-kappaB inhibitor acetyl-11-keto-beta-boswellic acid in LPS-challenged ApoE-/- mice. Arterioscler. Thromb. Vasc. Biol. 2008, 28:272-277.
75. Szyf M. Epigenetics, DNA methylation, and chromatin modifying drugs. Annu. Rev. Pharmacol. Toxicol. 2009, 49:243-263.
76. Bordone L., Guarente L. Calorie restriction, SIRT1 and metabolism: understanding longevity. Nat. Rev. Mol. Cell Biol. 2005, 6:298-305.
77. Banks A.S., Kon N., Knight C., Matsumoto M., Gutierrez-Juarez R., Rossetti L., Gu W., Accili D. SirT1 gain of function increases energy efficiency and prevents diabetes in mice. Cell Metab. 2008, 8:333-341.
78. Baur J.A., Pearson K.J., Price N.L., Jamieson H.A., Lerin C., Kalra A., Prabhu V.V., Allard J.S., Lopez-Lluch G., Lewis K., Pistell P.J., Poosala S., Becker K.G., Boss O., Gwinn D., Wang M., Ramaswamy S., Fishbein K.W., Spencer R.G., Lakatta E.G., Le Couteur D., Shaw R.J., Navas P., Puigserver P., Ingram D.K., de Cabo R., Sinclair D.A. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006, 444:337-342.
79. Lagouge M., Argmann C., Gerhart-Hines Z., Meziane H., Lerin C., Daussin F., Messadeq N., Milne J., Lambert P., Elliott P., Geny B., Laakso M., Puigserver P., Auwerx J. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 2006, 127:1109-1122.
80. Borra M.T., Smith B.C., Denu J.M. Mechanism of human SIRT1 activation by resveratrol. J. Biol. Chem. 2005, 280:17187-17195.
81. Milne J.C., Lambert P.D., Schenk S., Carney D.P., Smith J.J., Gagne D.J., Jin L., Boss O., Perni R.B., Vu C.B., Bemis J.E., Xie R., Disch J.S., Ng P.Y., Nunes J.J., Lynch A.V., Yang H., Galonek H., Israelian K., Choy W., Iffland A., Lavu S., Medvedik O., Sinclair D.A., Olefsky J.M., Jirousek M.R., Elliott P.J., Westphal C.H. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 2007, 450:712-716.
82. Yoshida M., Kijima M., Akita M., Beppu T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J. Biol. Chem. 1990, 265:17174-17179.
83. Susick L., Senanayake T., Veluthakal R., Woster P.M., Kowluru A. A novel histone deacetylase inhibitor prevents IL-1beta induced metabolic dysfunction in pancreatic beta-cells. J. Cell. Mol. Med. 2009, 13:1877-1885.
84. McGee S.L., Hargreaves M. Exercise and skeletal muscle glucose transporter 4 expression: molecular mechanisms. Clin. Exp. Pharmacol. Physiol. 2006, 33:395-399.